Inhibition of prothrombin activation by antiphospholipid antibodies and β2‐glycoprotein 1

No abstract is available for this paper.

• Publication year

  1994

• Venue

  British Journal of Haematology

• Publication date

  1994-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1365-2141.1994.tb08311.xPMID 7993795
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiphospholipid antibodies

  1994cited by this paper
• Are immunoglobulins with lupus anticoagulant activity specific for phospholipids?

  1993cited by this paper
• Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?

  1993cited by this paper
• β2‐glycoprotein 1 (β2GP1) enhances cardiolipin binding activity but is not the antigen for antiphospholipid antibodies

  1992cited by this paper
• Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I.

  1992cited by this paper
• Lupus Anticoagulant Activity Is Frequently Dependent on the Presence of β2-Glycoprotein I

  1992cited by this paper
• Anticoagulant Activity of β2-Glycoprotein I Is Potentiated by a Distinct Subgroup of Anticardiolipin Antibodies

  1992cited by this paper
• Beta 2-glycoprotein 1 (beta 2GP1) enhances cardiolipin binding activity but is not the antigen for antiphospholipid antibodies.

  1992cited by this paper
• Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes?

  1992cited by this paper
• Lupus anticoagulant.

  1991cited by this paper
• Assays for Phospholipid-Dependent Formation of Thrombin and Xa: A Potential Method for Quantifying Lupus Anticoagulant Activity

  1991cited by this paper
• Lupus Anticoagulant IgG's (LA) Are Not Directed to Phospholipids only, but to a Complex of Lipid-Bound Human Prothrombin

  1991cited by this paper
• Antiphospholipid antibodies.

  1990cited by this paper
• Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance.

  1990cited by this paper
• Inhibition of phospholipid and platelet‐dependent prothrombinase activity in the plasma of patients with lupus anticoagulants

  1989cited by this paper
• LABORATORY IDENTIFICATION OF THE LUPUS ANTICOAGULANT

  1989cited by this paper
• Lupus anticoagulants: misnomer, paradox, riddle, epiphenomenon.

  1988cited by this paper
• Statistical Inference for Continuous Variables

  1988cited by this paper
• Lupus anticoagulants: misnomer, paradox, riddle, epiphenomenon.

  1988cited by this paper
• Syndrome of the black swan.

  1987cited by this paper
• Immunological specificity and mechanism of action of IgG lupus anticoagulants.

  1987cited by this paper
• Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I.

  1986cited by this paper
• Prothrombinase activity of human platelets is inhibited by β2-glycoprotein-I

  1986cited by this paper
• Anti-phospholipid antibodies.

  1985cited by this paper
• Affinity purified anti-cardiolipin and anti-DNA antibodies.

  1985cited by this paper
• beta 2-Glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles.

  1984cited by this paper
• The Diagnosis of Lupus Anticoagulants by the Activated Partial Thromboplastin Time - The Central Role of Phosphatidyl Serine

  1984cited by this paper
• Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure.

  1983cited by this paper
• Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.

  1983cited by this paper
• Lupus anticoagulants.

  1982cited by this paper
• Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant.

  1980cited by this paper
• A Sensitive Test Demonstrating Lupus Anticoagulant and its Behavioural Patterns

  1978cited by this paper
• Circulating anticoagulant in disseminated lupus erythematosus. Proposed mode of action.

  1973cited by this paper
• A New Type of Coagulation Inhibitor

  1969cited by this paper
• Purification and kinetic studies on a circulating anticoagulant in a suspected case of lupus erythematosus.

  1965cited by this paper
• Purification and Kinetic Studies on a Circulating Anticoagulant in a Suspected Case of Lupus Erythematosus*

  1965cited by this paper

• Revisiting beta 2 glycoprotein I, the major autoantigen in the antiphospholipid syndrome.

  2012cites this paper
• Interaction of β2-Glycoprotein I with Lipopolysaccharide Leads to Toll-like Receptor 4 (TLR4)-dependent Activation of Macrophages*

  2011cites this paper
• Beta-2-glycoprotein 1-dependent macrophage uptake of apoptotic cells. Binding to lipoprotein receptor-related protein receptor family members.

  2008cites this paper
• Hypercoagulabilité associée aux anticorps anti-phospholipides : approches descriptives et mécanistiques

  2008influential citation
• Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis.

  2007cites this paper
• Plasmin-Cleaved β-2-Glycoprotein 1 Is an Inhibitor of Angiogenesis

  2007cites this paper
• A peptide that mimics the Vth region of β2glycoprotein I reverses antiphospholipid-mediated thrombosis in mice

  2006cites this paper
• Antiphospholipid antibodies and the antiphospholipid syndrome

  2004influential citation
• A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo.

  2004cites this paper
• β 2 -Glycoprotein I (Apolipoprotein H) Modulates Uptake and Endocytosis Associated Chemiluminescence in Rat Kupffer Cells

  2002cites this paper
• beta 2-glycoprotein I (apolipoprotein H) modulates uptake and endocytosis associated chemiluminescence in rat Kupffer cells.

  2002cites this paper
• The pathogenic potential of the anti-phospholipid antibodies associated with the antiphospholid syndrome and systemic lupus erythematosus.

  2002cites this paper
• Das Antiphospholipidsyndrom Pathogenese, molekulare Grundlagen und klinische Aspekte

  2001cites this paper
• Complexes of anti‐prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces

  2001cites this paper
• [Antiphospholipid syndrome. Pathogenesis, molecular basis and clinical aspects].

  2001cites this paper
• Antiphospholipid antibody-mediated interference with annexin-V anticoagulant activity

  2001cites this paper
• comment]Antigenic specificity of the "anticardiolipin" antibodies [letter;

  2000cites this paper
• The pathogenic role of annexin-V in the antiphospholipid syndrome

  2000cites this paper
• Antiphospholipid antibody-mediated disruption of the annexin-V antithrombotic shield: a thrombogenic mechanism for the antiphospholipid syndrome.

  2000cites this paper
• Antibody-Mediated Disruption of the Annexin-V Antithrombotic Shield: A New Mechanism for Thrombosis in the Antiphospholipid Syndrome

  1999cites this paper
• Opposite beta2-glycoprotein I requirement for the binding of infectious and autoimmune antiphospholipid antibodies to cardiolipin liposomes is associated with antibody avidity.

  1999cites this paper
• Beta2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies.

  1999cites this paper
• β2-Glycoprotein I Is Proteolytically Cleaved In Vivo upon Activation of Fibrinolysis

  1999cites this paper
• Clinical and laboratory manifestations of anti-factor V antibodies.

  1999cites this paper
• Systemic lupus erythematosus presenting with haemorrhagic manifestation.

  1999cites this paper
• Thrombogenic properties of antiphospholipid antibodies do not depend on their binding to β2 glycoprotein 1 (β2GP1) alone

  1998cites this paper
• Antiphospholipid antibody syndrome: new insights on thrombogenic mechanisms.

  1998cites this paper
• Thrombogenic properties of antiphospholipid antibodies do not depend on their binding to beta2 glycoprotein 1 (beta2GP1) alone.

  1998cites this paper
• Antiphospholipid Antibodies and Cerebral Lupus

  1997cites this paper
• Antiphospholipid antibody: functional specificity for inhibition of prothrombin activation by the prothrombinase complex

  1997cites this paper
• A new method for characterization and epitope determination of a lupus anticoagulant-associated neutralizing antiprothrombin antibody.

  1997cites this paper
• Antiphospholipid antibodies: standardization and testing.

  1997cites this paper
• [New biological factors of thromboses].

  1997cites this paper
• Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies.

  1996cites this paper
• Immunology of the antiphospholipid antibody syndrome.

  1996cites this paper
• Studies on the interaction of placental anticoagulant protein I, beta 2 glycoprotein 1, and antiphospholipid antibodies in the prothrombinase reaction and in the solid phase anticardiolipin assays.

  1996cites this paper
• Functional Effects of Anticardiolipin Antibodies

  1996cites this paper
• Antigenic Specificities of Antiphospholipid Autoantibodies: Implications for Clinical Laboratory Testing and Diagnosis of the Antiphospholipid Syndrome

  1996cites this paper
• The lupus anticoagulant/antiphospholipid syndrome.

  1996cites this paper
• Demonstration of antiphospholipid antibody heterogeneity by phospholipid column chromatography and salt gradient elution techniques

  1995cites this paper
• Phospholipid binding antibodies warrant continued investigation.

  1995cites this paper
• The antiphospholipid-protein syndrome

  1995cites this paper
• Comparison of the Effects of Anticardiolipin Antibodies from Patients with the Antiphospholipid Syndrome and with Syphilis on Platelet Activation and Aggregation

  1995cites this paper
• Antiphospholipid Antibodies in an in vivo Thrombosis Model in Mice

  1994cites this paper
• Differences in functional activity of anticardiolipin antibodies from patients with syphilis and those with antiphospholipid syndrome

  1994cites this paper